Psoriasis with metabolic syndrom
Conditions
Interventions
Control:Integrated therapy
metformin:Integrated therapy combined with Metformin hydrochloride
Liraglutide:Integrated therapy combined with Liraglutide
Sponsors
Department of Dermatology, Chinese PLA General Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Plaque psoriasis patients with metabolic syndrome were clinically or pathologically diagnosed as moderate to severe (PASI score > 5); 2. Aged over 18 years; 3. Accept standard comprehensive psoriasis treatment in our ward; 4. Agree to participate in the study and sign the informed consent
Exclusion criteria
Exclusion criteria: 1. Received glucocorticoid, immunosuppressive system therapy and other phototherapy within 3 months; 2. Preparetion of glucocorticoids, vitamin D derivatives and retinoic acid were used within and 2 weeks; 3. History of ultraviolet allergy and history of oral use of photosensitizers; 4. Symptoms and signs of joint pain, swelling, deformity, and limited movement; 5. Participating in other clinical studies; 6. Using other psoriasis treatment during the study period; 7. Using insulin sensitization therapy before participating in this study; 8. Women recently having family planning,pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| percentage of PASI75; | — |
Secondary
| Measure | Time frame |
|---|---|
| percentage of PASI90;percentage of PASI50;level of systemic inflammatory cytokines; | — |
Countries
China
Contacts
Public ContactLi Chengxin
Chinese PLA General Hospital
Outcome results
None listed